Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Is hepatitis B immunoglobulin necessary in prophylaxis of hepatitis B recurrence after liver transplantation? A meta-analysis.

PloS one - 1 Jan 2014

Wang Peijie, Tam Ngalei, Wang Haochen, Zheng Huanwei, Chen Philip, Wu Linwei, He Xiaoshun

Abstract excerpt

BACKGROUND & AIMS: Application of nucleoside analogues and hepatitis B immunoglobulin (HBIG) has reduced hepatitis B virus (HBV) recurrence rate after liver transplantation (LT) dramatically. Recent data suggests therapy without HBIG is also effective. We sought to evaluate the necessity of HBIG in prophylaxis of HBV recurrence after LT. METHODS: A meta-analysis was performed. PubMed/MEDLINE, Web of Knowledge and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA, Viral
Share to Hepatitis B
Share to Hepatitis B virus

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunoglobulins

Share to Liver Transplantation

Share to Mutation

Share to Recurrence

Source

Open in PubMed Open full text

Identifiers

PMID: 25102072
DOI: 10.1371/journal.pone.0104480
PMCID: PMC4125198

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Is hepatitis B immunoglobulin necessary in prophylaxis of hepatitis B recurrence after liver transplantation? A meta-analysis.PMID 25102072Read ↗

Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis.Semantic proximity Read ↗

Change of strategies and future perspectives against hepatitis B virus recurrence after liver transplantation.Semantic proximity Read ↗

Clinical-pathological analysis of hepatitis B virus recurrence after liver transplantation in Chinese patients.Semantic proximity Read ↗

Reevaluation of the effect of lamivudine therapy preoperative to prevent HBV recurrence after liver transplantation.Semantic proximity Read ↗

Prophylaxis and treatment of hepatitis B recurrence after liver transplantation in the antiviral era.Semantic proximity Read ↗

Posttransplantation prophylaxis with primary high-dose hepatitis B immunoglobulin monotherapy and complementary preemptive antiviral add-on.Semantic proximity Read ↗

High viremia, prolonged Lamivudine therapy and recurrent hepatocellular carcinoma predict posttransplant hepatitis B recurrence.Semantic proximity Read ↗

Hepatitis B and liver transplantation: molecular and clinical features that influence recurrence and outcome.Semantic proximity Read ↗

[Liver transplantation for complications of hepatitis B].Semantic proximity Read ↗

Efficacy of hepatitis B immunoglobulin in relation to the gene polymorphisms of human leukocyte Fcgamma receptor III (CD16) in Chinese liver transplant patients.Semantic proximity Read ↗

Section 13. Short-course pretransplant antiviral therapy is a feasible and effective strategy to prevent hepatitis C recurrence after liver transplantation in genotype 2 patients.Semantic proximity Read ↗

Prognosis in liver transplantation recipients after hepatitis B virus recurrence.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.